Dr Reddy’s Laboratories invests Rs 565 crore in Russian subsidiary, acquiring 45.19% stake for working capital needs.

Hyderabad: Dr. Reddy's Laboratories is gearing up to shake up the global weight-loss drug market with the launch of an ...

Dr. Reddy's Laboratories Ltd. closed 10.04% short of its 52-week high of 1,420.20 rupees, which the company achieved on August 21st.

Detailed price information for Dr. Reddy's Laboratories Ltd ADR (RDY-N) from The Globe and Mail including charting and trades.

Post-operative nausea and vomiting (PONV) market to rise from $2.11B in 2024 to $2.97B in 2029, driven by innovations in ...

Detailed price information for Dr. Reddy's Laboratories Ltd ADR (RDY-N) from The Globe and Mail including charting and trades.

Dr. Reddy's Laboratories has kicked off FY26 with double-digit growth. M.V. Ramana, CEO of Branded Markets (India & Emerging ...

Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 ...

Dr Reddy’s Laboratories ( ($RDY) ) has issued an update. On July 23, 2025, Dr. Reddy’s Laboratories announced its financial results for the ...

HYDERABAD, India (AP) — HYDERABAD, India (AP) — Dr. Reddy's Laboratories Ltd. (RDY) on Wednesday reported profit of $165 million in its fiscal first quarter. On a per-share basis, the Hyderabad, India ...

India’s Dr Reddy’s Laboratories Ltd. is gearing up to launch a generic version of semaglutide — the active ingredient in Novo ...

Dr. Reddy’s Laboratories ( NYSE: RDY) is preparing to launch a generic version of semaglutide, the active ingredient in Novo ...